1. Identification of Small and Non-Small Cell Lung Cancer Markers in Peripheral Blood Using Cytokinesis-Blocked Micronucleus and Spectral Karyotyping Assays
Cytogenet Genome Res 2017;152: DOI: /
Fig. 1. Frequency distribution of CBMN endpoints among the study groups. A BN-MN distribution among SCLC versus NSCLC and controls. B BN-NPB distribution among SCLC versus NSCLC and controls.
© 2017 S. Karger AG, Basel

2. Identification of Small and Non-Small Cell Lung Cancer Markers in Peripheral Blood Using Cytokinesis-Blocked Micronucleus and Spectral Karyotyping Assays
Cytogenet Genome Res 2017;152: DOI: /
Fig. 2. Frequency of specific chromosome involvement by endpoint and disease status as detected by SKY analysis. A Chromosome involvement in BN-MN. B Chromosome involvement in BN-NPB. C Chromosome involvement in BN-BUD.
© 2017 S. Karger AG, Basel

3. Identification of Small and Non-Small Cell Lung Cancer Markers in Peripheral Blood Using Cytokinesis-Blocked Micronucleus and Spectral Karyotyping Assays
Cytogenet Genome Res 2017;152: DOI: /
Table 1. Demographic characteristics of the SCLC cases, NSCLC cases, and controls
© 2017 S. Karger AG, Basel

4. Identification of Small and Non-Small Cell Lung Cancer Markers in Peripheral Blood Using Cytokinesis-Blocked Micronucleus and Spectral Karyotyping Assays
Cytogenet Genome Res 2017;152: DOI: /
Table 2. Overall frequencies of BN-MN, BN-NPBs, and BN-BUDs per 1,000 binucleated cells in SCLC cases, NSCLC cases, and controls
© 2017 S. Karger AG, Basel

5. Identification of Small and Non-Small Cell Lung Cancer Markers in Peripheral Blood Using Cytokinesis-Blocked Micronucleus and Spectral Karyotyping Assays
Cytogenet Genome Res 2017;152: DOI: /
Table 3. Risk estimates of SCLC and NSCLC for CBMN endpoints
© 2017 S. Karger AG, Basel